Trial Profile
A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects With Exploration of Food Effect
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs KM 819 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Kainos Medicines
- 31 Mar 2020 Status changed from recruiting to completed.
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 24 Jan 2017 New trial record